reports
BlackLine’s Signature Finance Transformation Event Returns to London a...
BlackLine’s Signature Finance Transformation Event Returns to London and Debuts in Paris LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- BlackLine is expanding the reach of its flagship finance transformation event, BeyondTheBlack, with two key events in Europe this June. BeyondTheBlack will return to London on June 17, followed by its debut in Paris on June 19, marking the first time the event has been held in France. Each event brings together finance and accounting leaders across industries to explore how world-class companies are achieving smarter, faster, and more scalable financial opera...
Myriad Genetics Announces Early Access to the FirstGene Multiple Prena...
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the validity and utility of the FirstGeneTM screen SALT LAKE CITY, June 03, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced early access to the FirstGeneTM Multiple Prenatal Screen. The company will begin a large study that will simultaneously delive...
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of ...
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via ultra-sensitive MRD SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the Na...
BlackLine Announces Participation in Upcoming Investor Conferences
BlackLine Announces Participation in Upcoming Investor Conferences LOS ANGELES, May 27, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL) today announced that BlackLine’s management team will participate in the following upcoming investor conferences: Baird 2025 Global Consumer, Technology & Services ConferenceTuesday, June 3, 2025Presentation time: 2:00 PM ETLocation: New York, NY William Blair 45th Annual Growth Stock ConferenceWednesday, June 4, 2025Presentation time: 10:40 AM CTLocation: Chicago, IL BMO Virtual Software ConferenceTuesday, June 10, 2025Presentation time: 12:15 PM ETLocation: ...
Myriad Genetics Highlights New Research Advancements and Oncology Inno...
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the . Myriad will also highlight how its comprehensive portfolio of genetic and tum...
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healt...
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences Correction: Time of BofA Conference SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025.Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025. Liv...
BlackLine Expands Agentic AI Capabilities to Accelerate Future-Ready F...
BlackLine Expands Agentic AI Capabilities to Accelerate Future-Ready Financial Operations With trusted, user-controlled AI embedded across its platform, BlackLine empowers the Office of the CFO to streamline operations, unlock insights, and confidently move toward autonomous finance LOS ANGELES, May 08, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL) today announced the continued expansion of its artificial intelligence (AI) capabilities, including new agents, delivering on its vision to power future-ready financial operations. With AI now embedded across every major financial workflow—from rec...
Myriad Genetics Announces RiskScore Study Published in JCO Precision O...
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk assessment tool integ...
BlackLine Announces First Quarter Financial Results
BlackLine Announces First Quarter Financial Results LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL), today announced financial results for the first quarter ended March 31, 2025. “BlackLine’s first quarter delivered solid results with bookings exceeding expectations, driven by improved execution along with continued margin expansion,” said Owen Ryan, Co-CEO of BlackLine. “Our key strategic initiatives continue to advance steadily: Studio360 adoption is growing, our new pricing strategy is gaining traction, our industry-specific approach is building momentum, and our public s...
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates ...
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, ben...
Concerns about Mental Health Medication Side Effects Remain a Barrier ...
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor More than half say genetic testing for mental health medications could reduce concerns SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medicatio...
Myriad Genetics to Release First Quarter 2025 Financial Results on May...
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 Management will participate in two upcoming investor healthcare conferences SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance ...
Myriad Genetics Highlights MRD Clinical Validity Data at American Asso...
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting Podium presentation showcases the clinical application of Precise™ MRD SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared at the American Association for Cancer Research (AACR) Annual Meeting that highlights the performance of the Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). A podium presentation titled ...
BlackLine Announces Date for First Quarter 2025 Earnings Release and C...
BlackLine Announces Date for First Quarter 2025 Earnings Release and Conference Call LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BL) announced today that it will release financial results for the first quarter ended March 31, 2025 after market close on Tuesday, May 6, 2025 followed by a conference call hosted by management at 2:00 p.m. PT / 5:00 p.m. ET. A live webcast and replay will be accessible on BlackLine’s investor relations website at . To access the conference call by phone, please register , and dial-in details will be provided. To avoid delays, we encourage partic...
Myriad Genetics Announces Study Results Show Patients with Depression ...
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing Study published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical Psychopharmacology has published a showing those with major depressive disorder had fewer psychiatric hospitalizations after taking the ® Psychotropic Test. “Millions of Americans face major depressive disorder each ...
BlackLine Recognized in Report on Top AI Use Cases for Accounts Receiv...
BlackLine Recognized in Report on Top AI Use Cases for Accounts Receivable Automation in 2025 Recognized by leading independent research firm for addressing model bias and inaccuracy—key to enabling verifiable, user-controlled AI for the Office of the CFO LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BL), has been recognized in the recently published Forrester Report: Top AI Use Cases for Accounts Receivable Automation in 2025. The report highlights key areas where artificial intelligence is transforming the accounts receivable (AR) function, with BlackLine cited for its cap...
Myriad Genetics Announces Inducement Awards
Myriad Genetics Announces Inducement Awards SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units equal to $3.75 million, comprising (i) time-based restricted stock units (RSUs) equal to $2 million and (ii) performance-based restricted stock units (PSUs) equal to $1.75 mill...
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative...
BlackLine Announces 2024 Partner Award Winners, Recognizing Excellence...
BlackLine Announces 2024 Partner Award Winners, Recognizing Excellence in Digital Finance Transformation Annual awards program recognizes top-performing partners driving digital transformation for the Office of the CFO LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL), the intelligent financial data platform that powers the modern Office of the CFO, has announced the winners of its 2024 Global and Regional Partner Awards, celebrating firms that have gone above and beyond in enabling organizations to achieve future-ready finance operations. This year’s honorees are recognize...
BlackLine Appoints New Member to Board of Directors in Collaboration w...
BlackLine Appoints New Member to Board of Directors in Collaboration with Scalar Gauge Fund Company adds independent director as part of mutual cooperation agreement LOS ANGELES, March 10, 2025 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL) (“BlackLine” or the “Company”) today announced that it has entered into a cooperation agreement (the “agreement”) with Scalar Gauge Fund (“Scalar Gauge”) to appoint a highly qualified and independent member to the Company’s Board of Directors (the “Board”). In accordance with the agreement with Scalar Gauge, the Company will appoint Scott Davidson...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.